ArticlePLOS global public health2024
State and territory immunization program activities and their association with human papillomavirus vaccine initiation in the United States of America: A multilevel approach.
Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study evaluates the association between immunization program (IP) activities aimed at increasing HPV vaccination among adolescents and their impact on initiation rates. Our data sources are: (i) 2016 AIM Annual Survey and (ii) 2019 National Immunization Survey-Teen. We estimated the prevalence of HPV vaccine initiation using a multilevel Poisson model, combining state-level IP data and individual characteristics of adolescents. We calculated the prevalence ratio (PR) of HPV initiation among adolescents to compare the effects of IP activities, adjusting for state of residence, age, sex, maternal education, and ethnicity. A total of 17,390 teens aged 13 and 17 were evaluated. States with publicly available school-based adolescent coverage rates and/or exemptions (PRw, activity Dadjusted: 1.08, 95% CI: 1.02, 1.14), and those that expanded the number of pharmacies entering HPV vaccination data (PRw, activity Nadjusted; 1.06, 95% CI: 1.02, 1.10) in Immunization Information Systems (IIS), had higher HPV vaccine initiation rates compared to states that did not implement these strategies. When stratifying, these findings were present in the younger group (13-15 years, PRw, activity D adjusted: 1.10, 95% CI: 1.01, 1.18; PRw. activity N adjusted: 1.10, 95% CI: 1.05, 1.16), but not in the older group (16-17 years, PRw, activity D adjusted: 1.05, 95% CI: 0.95, 1.15; PRw. activity N adjusted: 1.00, 95% CI: 0.94, 1.06). States that expanded the number of school-located programs entering HPV vaccine records in IIS (PRw, activity Eadjusted: 1.08, 95% CI: 1.01, 1.15) had higher vaccine initiation prevalence in the younger group but not in the older group. Limitations include a lack of operational definitions for IP activities, potential biases in the NIS-Teen survey, and reliance on provider-reported HPV vaccination. Nonetheless, these results highlight immunization activities that support national efforts to increase HPV vaccine uptake and inform public health programs on effective HPV vaccine promotion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.